Objective: To screen gene mutation in alpha-galactosidase A (alpha-Gal A) in a nonconsanguineous Chinese family with Fabry disease (FD) with clinical manifestations similar to hypertrophic cardiomyopathy (HCM).
Methods: Mutation analysis was performed by using purified PCR products to direct sequence analysis on an ABI-377XL automated DNA sequencer. DNA analysis of alpha-Gal A gene and physical and clinical examinations were performed in a female proband and in her relatives (15 subjects in total).
Results: Three hemizygotes and 6 heterozygotes were diagnosed for FD by the alpha-Gal A gene analysis with a missense mutation in exon 5 of the alpha-Gal A sequence, leading to a TGG32TGA substitution, which may induce the absent of tryptophan's translation (corresponded to TGG) by the terminator codon TGA. Six patients in the family were revealed as HCM by echocardiography.
Conclusions: Present results show that it is important to differentiate FD from other causes of hypertrophy in patients with cardiac hypertrophy. Screening for alpha-Gal A gene mutations in patients with FD and in their relatives could help to identify all suspected cases within the families.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Generation of a human induced pluripotent stem cell lines (UKJi003-A) from a patient with Fabry disease and healthy donor (UKJi004-A).
Stem Cell Res
December 2024
Department of Internal Medicine I, Division of Cardiology, University Hospital Jena, FSU Jena, Germany.
Fabry disease (FD, OMIM #301500) is a rare metabolic disorder, X-linked glycosphingolipidosis that is characterized by pathogenic mutations in the GLA (Galactosidase Alpha) gene (OMIM *300644) that result in reduced α-galactosidase A (α-GAL) activity and accumulation of globotriaosylceramide (Gb3) in tissues and organs. Peripheral blood mononuclear cells (PBMCs) were used to generate human induced pluripotent stem cells (hiPSC). UKJi004-A was produced from a healthy donor, whereas UKJi003-A was produced from a patient who had FD with GLA-mutation (IVS6-10G>A).
View Article and Find Full Text PDFCharacterization of antibodies induced by immunization of mice with isoglobotrihexosylceramide (iGb3).
Biochem Biophys Rep
December 2024
Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 1-8-31 Midorigaoka, Ikeda, Osaka, 563-8577, Japan.
Article Synopsis
- Isoglobotrihexosylceramide (iGb3) is identified as a natural killer T cell ligand and a glycosphingolipid with the α-Gal epitope structure, and its immunogenicity was explored in both mice and human subjects.
- The study found no IgE antibodies reactive to iGb3 in MRL/lpr mice or healthy humans, and no IgE or IgG production was induced in mice immunized with iGb3, indicating it lacks sufficient immunogenicity.
- A monoclonal antibody specific to iGb3 showed significant similarity to antibodies that recognize glycoconjugates with α-linked galactose structures, suggesting the presence of corresponding antibody-encoding genes but confirming
Identification of c.146G > A mutation in a Fabry patient and its correction by customized Cas9 base editors in vitro.
Int J Biol Macromol
December 2024
Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address:
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to reduced α-galactosidase (α-Gal A) activity. Current treatments, like enzyme replacement, have limitations affecting efficacy and patient outcomes. CRISPR/Cas9 genome editing tools may offer the potential to develop therapeutic strategy via correcting GLA mutations.
View Article and Find Full Text PDFInfrared spectroscopy as a new approach for early fabry disease screening: a pilot study.
Orphanet J Rare Dis
October 2024
Postgraduate Program in Health Sciences, State University of Santa Cruz, Ilhéus, 45662-900, Bahia, Brazil.
Article Synopsis
- Fabry disease (FD) is a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase-A due to mutations in the GLA gene, leading to harmful lipid accumulation in cells and primarily affecting males.
- The study investigates the use of attenuated total reflection Fourier-transform IR (ATR-FTIR) spectroscopy to analyze plasma samples and identify a distinct molecular profile in FD patients compared to healthy controls, achieving perfect accuracy in differentiating the two groups.
- The findings suggest that ATR-FTIR spectroscopy, combined with advanced pattern recognition algorithms, could serve as a quick and cost-effective screening method for Fabry disease, applicable to all genders.
Assessment of combined α-GAL enzyme activity and lyso-GL3 for Fabry disease screening in women with chronic kidney disease.
Mol Genet Metab
October 2024
Department of Internal Medicine - UNESP, Univ Estadual Paulista, Brazil.
Introduction: The spectrum of clinical presentation of Fabry disease (FD) in women is broad and challenging. The aim is to evaluate the effectiveness of an alternative screening method for FD in women.
Methods: A collaborative multicenter cross-sectional study to evaluate the sensitivity and specificity of the combination of two tests (α-GAL enzyme activity assay and lyso-GL3 assay) for the diagnosis of FD in women.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!